{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T14:11:11Z","timestamp":1779718271353,"version":"3.53.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,25]]},"DOI":"10.7759\/cureus.109607","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T13:16:44Z","timestamp":1779715004000},"source":"Crossref","is-referenced-by-count":0,"title":["Cardiovascular Implications of Diabetes Mellitus: A Systematic Literature Review"],"prefix":"10.7759","author":[{"given":"Piyush Kumar","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand","family":"Sekar G","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram","family":"Diwakar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niyanta Ashokkumar","family":"Panchal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anshul","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anupravo","family":"Bhaumik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-025-03185-9","article-title":"Diabetes mellitus and associated vascular disease: pathogenesis, complications, and evolving treatments","volume":"42","author":"Islam K","year":"2025","unstructured":"Islam K, Islam R, Nguyen I, et al.. Diabetes mellitus and associated vascular disease: pathogenesis, complications, and evolving treatments. Adv Ther. 2025, 42:2659-78. 10.1007\/s12325-025-03185-9","journal-title":"Adv Ther"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-023-00877-z","article-title":"Cardiovascular risk in diabetes mellitus: epidemiology, assessment and prevention","volume":"20","author":"Wong ND","year":"2023","unstructured":"Wong ND, Sattar N. Cardiovascular risk in diabetes mellitus: epidemiology, assessment and prevention. Nat Rev Cardiol. 2023, 20:685-95. 10.1038\/s41569-023-00877-z","journal-title":"Nat Rev Cardiol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.117.311849","article-title":"Reducing the global burden of cardiovascular disease, part 2: prevention and treatment of cardiovascular disease","volume":"121","author":"Leong DP","year":"2017","unstructured":"Leong DP, Joseph PG, McKee M, Anand SS, Teo KK, Schwalm JD, Yusuf S. Reducing the global burden of cardiovascular disease, part 2: prevention and treatment of cardiovascular disease. Circ Res. 2017, 121:695-710. 10.1161\/CIRCRESAHA.117.311849","journal-title":"Circ Res"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-019-0860-y","article-title":"Metformin in patients with and without diabetes: a paradigm shift in cardiovascular disease management","volume":"18","author":"Luo F","year":"2019","unstructured":"Luo F, Das A, Chen J, Wu P, Li X, Fang Z. Metformin in patients with and without diabetes: a paradigm shift in cardiovascular disease management. Cardiovasc Diabetol. 2019, 18:54. 10.1186\/s12933-019-0860-y","journal-title":"Cardiovasc Diabetol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2023.166834","article-title":"Fetoplacental endothelial dysfunction in gestational diabetes mellitus and maternal obesity: a potential threat for programming cardiovascular disease","volume":"1869","author":"Diniz MS","year":"2023","unstructured":"Diniz MS, Hiden U, Falc\u00e3o-Pires I, Oliveira PJ, Sobrevia L, Pereira SP. Fetoplacental endothelial dysfunction in gestational diabetes mellitus and maternal obesity: a potential threat for programming cardiovascular disease. Biochim Biophys Acta Mol Basis Dis. 2023, 1869:166834. 10.1016\/j.bbadis.2023.166834","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)91401-s","article-title":"Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus","volume":"340","author":"Stehouwer CD","year":"1992","unstructured":"Stehouwer CD, Nauta JJ, Zeldenrust GC, Hackeng WH, Donker AJ, den Ottolander GJ. Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus. Lancet. 1992, 340:319-23. 10.1016\/0140-6736(92)91401-s","journal-title":"Lancet"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.4239\/wjd.v6.i13.1246","article-title":"Diabetes and cardiovascular disease: Epidemiology, biological mechanisms, treatment recommendations and future research","volume":"6","author":"Leon BM","year":"2015","unstructured":"Leon BM, Maddox TM. Diabetes and cardiovascular disease: Epidemiology, biological mechanisms, treatment recommendations and future research. World J Diabetes. 2015, 6:1246-58. 10.4239\/wjd.v6.i13.1246","journal-title":"World J Diabetes"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.851941","article-title":"Endothelial dysfunction and diabetic cardiomyopathy","volume":"13","author":"Wang M","year":"2022","unstructured":"Wang M, Li Y, Li S, Lv J. Endothelial dysfunction and diabetic cardiomyopathy. Front Endocrinol (Lausanne). 2022, 13:851941. 10.3389\/fendo.2022.851941","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241713381","article-title":"Advances in research on type 2 diabetes mellitus targets and therapeutic agents","volume":"24","author":"Su J","year":"2023","unstructured":"Su J, Luo Y, Hu S, Tang L, Ouyang S. Advances in research on type 2 diabetes mellitus targets and therapeutic agents. Int J Mol Sci. 2023, 24:13381. 10.3390\/ijms241713381","journal-title":"Int J Mol Sci"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3390\/nu16010027","article-title":"The importance of nutrition in menopause and perimenopause-a review","volume":"16","author":"Erd\u00e9lyi A","year":"2023","unstructured":"Erd\u00e9lyi A, P\u00e1lfi E, T\u0171\u0171 L, et al.. The importance of nutrition in menopause and perimenopause-a review. Nutrients. 2023, 16:27. 10.3390\/nu16010027","journal-title":"Nutrients"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21051835","article-title":"The Diabetes mellitus-atherosclerosis connection: the role of lipid and glucose metabolism and chronic inflammation","volume":"21","author":"Poznyak A","year":"2020","unstructured":"Poznyak A, Grechko AV, Poggio P, Myasoedova VA, Alfieri V, Orekhov AN. The Diabetes mellitus-atherosclerosis connection: the role of lipid and glucose metabolism and chronic inflammation. Int J Mol Sci. 2020, 21:1835. 10.3390\/ijms21051835","journal-title":"Int J Mol Sci"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3390\/publications14010004","article-title":"The Newcastle-Ottawa Scale for assessing the quality of studies in systematic reviews","volume":"14","author":"Gualdi-Russo E","year":"2026","unstructured":"Gualdi-Russo E, Zaccagni L. The Newcastle-Ottawa Scale for assessing the quality of studies in systematic reviews. Publications. 2026, 14:4. 10.3390\/publications14010004","journal-title":"Publications"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso SP","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, et al.. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016, 375:311-22. 10.1056\/NEJMoa1603827","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal R","year":"2022","unstructured":"Agarwal R, Filippatos G, Pitt B, et al.. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022, 43:474-84. 10.1093\/eurheartj\/ehab777","journal-title":"Eur Heart J"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01659-1","article-title":"The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial","volume":"28","author":"Voors AA","year":"2022","unstructured":"Voors AA, Angermann CE, Teerlink JR, et al.. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med. 2022, 28:568-74. 10.1038\/s41591-021-01659-1","journal-title":"Nat Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.034222","article-title":"Canagliflozin and heart failure in type 2 diabetes mellitus: results from the CANVAS program","volume":"138","author":"R\u00e5dholm K","year":"2018","unstructured":"R\u00e5dholm K, Figtree G, Perkovic V, et al.. Canagliflozin and heart failure in type 2 diabetes mellitus: results from the CANVAS program. Circulation. 2018, 138:458-68. 10.1161\/CIRCULATIONAHA.118.034222","journal-title":"Circulation"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-024-02472-z","article-title":"Impact of diabetes mellitus on right ventricular dysfunction and ventricular interdependence in hypertensive patients with heart failure with reduced ejection fraction assessed via 3.0 T cardiac MRI","volume":"23","author":"Zhang G","year":"2024","unstructured":"Zhang G, Shi R, Li XM, et al.. Impact of diabetes mellitus on right ventricular dysfunction and ventricular interdependence in hypertensive patients with heart failure with reduced ejection fraction assessed via 3.0 T cardiac MRI. Cardiovasc Diabetol. 2024, 23:375. 10.1186\/s12933-024-02472-z","journal-title":"Cardiovasc Diabetol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-018-4644-9","article-title":"Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME\u00ae randomised trial","volume":"61","author":"Verma S","year":"2018","unstructured":"Verma S, Mazer CD, Fitchett D, Inzucchi SE, Pfarr E, George JT, Zinman B. Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME\u00ae randomised trial. Diabetologia. 2018, 61:1712-23. 10.1007\/s00125-018-4644-9","journal-title":"Diabetologia"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2022.10.019","article-title":"Effects of diet on 10-year atherosclerotic cardiovascular disease risk (from the DASH trial)","volume":"187","author":"Jeong SY","year":"2023","unstructured":"Jeong SY, Wee CC, Kovell LC, et al.. Effects of diet on 10-year atherosclerotic cardiovascular disease risk (from the DASH trial). Am J Cardiol. 2023, 187:10-7. 10.1016\/j.amjcard.2022.10.019","journal-title":"Am J Cardiol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.3478","article-title":"Cardiovascular outcomes with exenatide in type 2 diabetes according to ejection fraction: The EXSCEL trial","volume":"27","author":"Neves JS","year":"2025","unstructured":"Neves JS, Leite AR, Mentz RJ, et al.. Cardiovascular outcomes with exenatide in type 2 diabetes according to ejection fraction: The EXSCEL trial. Eur J Heart Fail. 2025, 27:540-51. 10.1002\/ejhf.3478","journal-title":"Eur J Heart Fail"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.121.057983","article-title":"Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: analyses from the FIGARO-DKD trial","volume":"145","author":"Filippatos G","year":"2022","unstructured":"Filippatos G, Anker SD, Agarwal R, et al.. Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: analyses from the FIGARO-DKD trial. Circulation. 2022, 145:437-47. 10.1161\/CIRCULATIONAHA.121.057983","journal-title":"Circulation"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2200436","article-title":"Glycemia reduction in type 2 diabetes - microvascular and cardiovascular outcomes","volume":"387","author":"Nathan DM","year":"2022","unstructured":"Nathan DM, Lachin JM, Bebu I, et al.. Glycemia reduction in type 2 diabetes - microvascular and cardiovascular outcomes. N Engl J Med. 2022, 387:1075-88. 10.1056\/NEJMoa2200436","journal-title":"N Engl J Med"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.036068","article-title":"Glycemic control, cardiac autoimmunity, and long-term risk of cardiovascular disease in type 1 diabetes mellitus","volume":"139","author":"Sousa GR","year":"2019","unstructured":"Sousa GR, Pober D, Galderisi A, et al.. Glycemic control, cardiac autoimmunity, and long-term risk of cardiovascular disease in type 1 diabetes mellitus. Circulation. 2019, 139:730-43. 10.1161\/CIRCULATIONAHA.118.036068","journal-title":"Circulation"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26031094","article-title":"Type 2 diabetes mellitus: new pathogenetic mechanisms, treatment and the most important complications","volume":"26","author":"M\u0142ynarska E","year":"2025","unstructured":"M\u0142ynarska E, Czarnik W, Dzie\u017ca N, et al.. Type 2 diabetes mellitus: new pathogenetic mechanisms, treatment and the most important complications. Int J Mol Sci. 2025, 26:1094. 10.3390\/ijms26031094","journal-title":"Int J Mol Sci"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1155\/jdr\/8540354","article-title":"Sodium-glucose cotransporter 2 inhibitors in diabetic solid organ transplant recipients: a systematic review and meta-analysis of comparative studies","volume":"2026","author":"Geum MJ","year":"2026","unstructured":"Geum MJ, Oh KS, Ah YM. Sodium-glucose cotransporter 2 inhibitors in diabetic solid organ transplant recipients: a systematic review and meta-analysis of comparative studies. J Diabetes Res. 2026, 2026:8540354. 10.1155\/jdr\/8540354","journal-title":"J Diabetes Res"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1239335","article-title":"Statins and risk of type 2 diabetes: mechanism and clinical implications","volume":"14","author":"Laakso M","year":"2023","unstructured":"Laakso M, Fernandes Silva L. Statins and risk of type 2 diabetes: mechanism and clinical implications. Front Endocrinol (Lausanne). 2023, 14:1239335. 10.3389\/fendo.2023.1239335","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.109146","article-title":"Comparison of effects of SGLT-2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in type 2 diabetes mellitus patients with\/without albuminuria: a systematic review and network meta-analysis","volume":"183","author":"Kawai Y","year":"2022","unstructured":"Kawai Y, Uneda K, Yamada T, et al.. Comparison of effects of SGLT-2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in type 2 diabetes mellitus patients with\/without albuminuria: a systematic review and network meta-analysis. Diabetes Res Clin Pract. 2022, 183:109146. 10.1016\/j.diabres.2021.109146","journal-title":"Diabetes Res Clin Pract"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/488089-cardiovascular-implications-of-diabetes-mellitus-a-systematic-literature-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T13:16:45Z","timestamp":1779715005000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/488089-cardiovascular-implications-of-diabetes-mellitus-a-systematic-literature-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,25]]},"references-count":29,"URL":"https:\/\/doi.org\/10.7759\/cureus.109607","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,25]]}}}